Posted On: 09/03/2014 3:28:28 AM
Post# of 273350
Aryx Therapeutics (ARYX) 0.0062 $ARYX
SarlaFlex Inc. Closes $13 Million in NMTC Financing for New U.S. Facility
Marketwire - Fri Jan 17, 8:35AM CST
SarlaFlex Inc. has secured $13 million in New Markets Tax Credit (NMTC) allocation from Los Angeles-based National New Markets Fund, LLC (NNMF) to redevelop a manufacturing facility in rural South Carolina into the company's first U.S. based yarn and thread plant. U.S. Bank serves as the tax credit investor, capitalizing the allocation.
Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2012
M2 - Thu Jul 11, 11:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rqxvxn/functional_non) has announced the addition of the "Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2012" report to their offering. This report provides an overview of the Functional (Non Ulcer) Dyspepsia therapeutic pipeline. This report provides information on the therapeutic development for Functional (Non Ulcer) Dyspepsia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Functional (Non Ulcer) Dyspepsia. 'Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2012' is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team of experts. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERA
SarlaFlex Inc. Closes $13 Million in NMTC Financing for New U.S. Facility
Marketwire - Fri Jan 17, 8:35AM CST
SarlaFlex Inc. has secured $13 million in New Markets Tax Credit (NMTC) allocation from Los Angeles-based National New Markets Fund, LLC (NNMF) to redevelop a manufacturing facility in rural South Carolina into the company's first U.S. based yarn and thread plant. U.S. Bank serves as the tax credit investor, capitalizing the allocation.
Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2012
M2 - Thu Jul 11, 11:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rqxvxn/functional_non) has announced the addition of the "Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2012" report to their offering. This report provides an overview of the Functional (Non Ulcer) Dyspepsia therapeutic pipeline. This report provides information on the therapeutic development for Functional (Non Ulcer) Dyspepsia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Functional (Non Ulcer) Dyspepsia. 'Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2012' is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team of experts. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERA
(0)
(0)
